Dr. Ralph H. Silverman DDS initiated and developed his theories and technologies, espoused on this website, at The University of Illinois School of Basic Sciences, Chicago, as a non-salaried research associate from 1980 to 1984. The normal human molecules that he purified from normal human fibroblasts showed good promises as an anti-cancer agent for several standard mouse cancer models.
Meeting Dr. Clyde R. Goodheart MD MS MBA, in the fall of 1984, and showing him his research materials, resulted in a collaborative effort, and the founding of Fibrogenex, Inc. They started to produce human cellular fibronectin which was sold to the research market. Fibrogenex, with several SBIR grants, and cooperative research studies with cancer research scientist at Evanston Hospital, showed that their human and murine cellular fibronectin inhibited tumor recurrence at wound sites, in in vivo mouse studies. This was shown in liver, brain and thigh.
Dr. Silverman designed a periodontal disease kit, The Fibofil Perio Kit, that was used in a FDA/IRB approved clinical trial at UCLA, sponsored by Fibrogenex. The application of the human cellular fibronectin completely healed the chronically infected periodontal tissue with no side effects.
Fibrogenex inc., became CHIFYX in order to distinguish it from a a new biotech company Fibrogen. The cellular fibronectin that was sold to the research community resulted in many published papers utilizing this unique product. However, the challenges of attaining fresh biological material from which to create this product resulted in the closing of the CHIFYX laboratory. Nonetheless, in order to fulfill the promise of Regenerative Medicine, access to these essential building blocks of life and healing must be available to the research and clinical community.
There is continuing research evidence that Human Placental tissues may be able to produce normal human molecules that have the potential to treat a myriad of dyer clinical conditions. Placental cells are deemed fetal, and these readily available tissues may be the ultimate path to fulfill the goal of Regenerative Medicine. A small biotech company has already utilized a unique technology with placental cells and are already involved in clinical trials for different clinical conditions. We shall monitor their progress with great expectations.
A PROFESSIONAL ACTIVITIES
Research Associate (non-salaried) Departments of Physiology and Microbiology, University of Illinois, School of Basic Sciences, 1975-1984.
World Health Organization (WHO) Consultant in the Region of the Western Pacific
Oral Health Advisory Service in Malaysia, Singapore and the Philippines, August 8 to 31, 1978.
Advisor to the National Cancer Institute (NCI), research project of isolating antineoplastic Tyrosinase-Inhibitor Complex fromcommom mushrooms at the Frederick Cancer Research Center, Trederick MD, January 1977 and May 1977.
World Health Organization Advisor in the Region of the Western Pacific. Participant in WHO working group on Dental Health Education of the public, Kuala Lumpur, Malaysia, October 11 to 22, 1976.
Increasing Clinical Productivity and Coverage, Silverman RH WHO, Region of the Western Pacific. 1978.
Employing the Movable Dental Chair (MDC) for Expanded Auxiliary Function.
Silverman RH, Quintessence International, vol. 9, October, 1978.
Cellular and Plasma Fibronectins, Goodheart CR and Silverman RH, SIM Microbiology, vol. 41 No.6 1991.
The Role of Fibronectin in Tumor Implantation at the Surgical Sites, Murphy MS, Scanlon EF, Silverman RH, Goodheart CR, Goldschmidt RA, Jelachhich ML,. Clinical and Experimental Metastasis, vol.11, No. 2, 1993.
Denture Securing Apparatus. Pantent No. 3,514,858
Squeak-A-Dent Interdental Stimulator Patent No. 3,672,378
Dental Operative System. Patent No. 3,757,420
Profipel Complex for Treating Chronic Degenerative Disease. Patent No. 4,728,637
Method for Treating Cancer Resections. Patent No. 5,354,269
Method for Preparing Cellular Fibronectin. Patent No. 5,750,378